secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001558370-22-012218
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage reports Q2 2022 net loss of $1.3M; raises $5.1M in private placement
-----------------------------------------------------------------------------

- Net loss of $1.3M ($0.12 per share) vs $0.4M loss in Q2 2021; increase due to higher legal costs and prior-year PPP loan forgiveness.
- Completed private placement in May 2022, generating net proceeds of ~$5.1M to fund clinical development of Biostage Esophageal Implant (BEI).
- Operating cash on-hand of $4.6M as of June 30, 2022; expected runway into Q2 2023.
- Executed settlement with Harvard Bioscience and plaintiffs in wrongful death litigation; no admission of liability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000155837022012218/0001558370-22-012218-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000155837022012218/tmb-20220804x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-012218

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer